@article{ae19684238f54e20bfee3cedfe853e27,
title = "Outcome Prediction Based on Automatically Extracted Infarct Core Image Features in Patients with Acute Ischemic Stroke",
abstract = "Infarct volume (FIV) on follow-up diffusion-weighted imaging (FU-DWI) is only moderately associated with functional outcome in acute ischemic stroke patients. However, FU-DWI may contain other imaging biomarkers that could aid in improving outcome prediction models for acute ischemic stroke. We included FU-DWI data from the HERMES, ISLES, and MR CLEAN-NO IV databases. Lesions were segmented using a deep learning model trained on the HERMES and ISLES datasets. We assessed the performance of three classifiers in predicting functional independence for the MR CLEAN-NO IV trial cohort based on: (1) FIV alone, (2) the most important features obtained from a trained convolutional autoencoder (CAE), and (3) radiomics. Furthermore, we investigated feature importance in the radiomic-feature-based model. For outcome prediction, we included 206 patients: 144 scans were included in the training set, 21 in the validation set, and 41 in the test set. The classifiers that included the CAE and the radiomic features showed AUC values of 0.88 and 0.81, respectively, while the model based on FIV had an AUC of 0.79. This difference was not found to be statistically significant. Feature importance results showed that lesion intensity heterogeneity received more weight than lesion volume in outcome prediction. This study suggests that predictions of functional outcome should not be based on FIV alone and that FU-DWI images capture additional prognostic information.",
author = "Tolhuisen, {Manon L} and Hoving, {Jan W} and Koopman, {Miou S} and Manon Kappelhof and {van Voorst}, Henk and Bruggeman, {Agnetha E} and Demchuck, {Adam M} and Dippel, {Diederik W J} and Emmer, {Bart J} and Serge Bracard and Francis Guillemin and {van Oostenbrugge}, {Robert J} and Mitchell, {Peter J} and {van Zwam}, {Wim H} and Hill, {Michael D} and Roos, {Yvo B W E M} and Jovin, {Tudor G} and Berkhemer, {Olvert A} and Campbell, {Bruce C V} and Jeffrey Saver and Phil White and Muir, {Keith W} and Mayank Goyal and Marquering, {Henk A} and Majoie, {Charles B} and Caan, {Matthan W A} and {MR CLEAN-NO IV Investigators} and {HERMES Investigators}",
note = "Funding Information: The CONTRAST consortium is supported by the Netherlands Cardiovascular Research Initiative (CVON), an initiative of the Dutch Heart Foundation, and by the Brain Foundation Netherlands, Medtronic, and Cerenovus. AMC and Erasmus MC received additional unrestricted funding on behalf of CONTRAST for the execution of MR CLEAN-NO IV from Stryker European Operations BV. Funding Information: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Dr. Majoie reports grants from CVON/the Dutch Heart Foundation, the TWIN Foundation, the European Commission, the Dutch Health Evaluation program, and Stryker outside the submitted work (paid to the institution) and is a shareholder of Nico.lab International Ltd. A. van der Lugt and D.W.J. Dippel are the recipients of unrestricted grants from the Dutch Heart Foundation, the Dutch Brain Foundation, the Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Science, Stryker, Medtronic, Penumbra Inc., and Cerenovus for the conduct of trials regarding acute treatment for stroke. Dr. Caan reports a grant of the TKI-PPP program, co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health and is a shareholder of Nico.lab Inter- national Ltd. Dr. H.A. Marquering is a co-founder and shareholder of Nico.lab International Ltd. Dr. Saver is an employee of the University of California. The University of California has patent rights in retrieval devices for stroke. The University of California Regents received payments, on the basis of clinical trial contracts, for the number of subjects enrolled in multicenter clinical trials sponsored by Medtronic, Stryker, Cerenovus, and Rapid Medical; Dr. Saver served as an unpaid site investigator under these contracts. Dr. Saver has received contracted hourly payments and travel reimbursement for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker, and Cerenovus. Dr. Saver has received contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical. Prof. White declares institutional un-restricted educational grants from Medtronic, Penumbra, and Stryker, an institutional grant from Microvention, and personal consultancy work for Microvention. Prof. K. Muir has received fees for advisory board roles or speaking from Boehringer Ingelheim, Biogen, Bayer, Daiichi Sankyo, and ReNeuron, and receives institutional support from Boehringer Ingelheim for the ATTEST-2 trial. Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = jul,
day = "23",
doi = "10.3390/diagnostics12081786",
language = "English",
volume = "12",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI",
number = "8",
}